PMID- 32481293
OWN - NLM
STAT- MEDLINE
DCOM- 20200618
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 21
DP  - 2020 May 22
TI  - A systematic review and meta-analysis to compare the efficacy of conbercept with 
      ranibizumab in patients with macular edema secondary to retinal vein occlusion.
PG  - e20222
LID - 10.1097/MD.0000000000020222 [doi]
LID - e20222
AB  - BACKGROUND: The objective of this review and meta-analysis is to investigate the 
      efficacy of conbercept and ranibizumab, combined with or without laser 
      photocoagulation, in patients with macular edema secondary to retinal vein 
      occlusion (RVO-ME). METHODS: Several databases have been used to identify 
      relevant publications. After screening, a meta-analysis was conducted to compare 
      conbercept and ranibizumab with the support of RevMan 5.3 (Cochrane Library 
      Software, Oxford, UK). RESULTS: In this study, 9 randomized controlled trials and 
      6 retrospective trials were included with a total of 1180 patients. No 
      significant difference was found in best corrected visual acuity (BCVA) or 
      central macular thickness (CMT) in the baseline parameters [BCVA (weighted mean 
      difference (WMD): -0.01; 95% confidence interval CI: -0.03 to 0.01; P = .17), CMT 
      (WMD: 20.14; 95% CI: -26.70 to 66.97; P = .40). No significant differences were 
      found in the improvements of BCVA and adverse events (AEs) between the 2 groups 
      after injection of loading dosage [the 1st month BCVA (WMD: -0.01; 95% CI: -0.04 
      to 0.02; P = .54),the 3rd month BCVA (WMD: -0.02; 95% CI: --0.05 to 0.01; 
      P = .23), the 6th month BCVA (WMD: -0.02; 95% CI: -0.05 to 0.01; P = .27), AEs 
      (odds ratio: 0.84; 95% CI: 0.38 to 1.84; P = .66)]. However, there were 
      significant differences between conbercept and ranibizumab treatment in terms of 
      CMT [1st month CMT (WMD: -11.70; 95% CI: -19.71 to -3.68; P < .01), 3rd month CMT 
      (WMD: -10.08; 95% CI: -15.62 to -4.53; P < .01), 6th month CMT (WMD: -15.83; 95% 
      CI: -22.88 to -8.78; P < .01)] and the number of injections (WMD, -0.36; 95% CI: 
      -0.68 to -0.04; P = .03). CONCLUSION: The current pooled evidence suggested that 
      both therapies of intravitreal conbercept and intravitreal ranibizumab with or 
      without laser photocoagulation are effective in vision function in RVO-ME 
      patients, and confirmed that conbercept has advantages over ranibizumab in terms 
      of CMT and the number of injections for treating RVO-ME. In addition, conbercept 
      has the statistically same visual gains and safety as ranibizumab in RVO-ME 
      patients. Longer-term follow-up surveys on the safety and effectiveness of these 
      2 treatment regimens are required.
FAU - Liu, Weishai
AU  - Liu W
AD  - Department of Ophthalmology, The First hospital of Shanxi Medical University, 
      Taiyuan City.
FAU - Li, Yanjie
AU  - Li Y
AD  - Department of Ophthalmology, The First hospital of Shanxi Medical University, 
      Taiyuan City.
FAU - Cao, Rongxia
AU  - Cao R
AD  - Department of Ophthalmology, The First hospital of Shanxi Medical University, 
      Taiyuan City.
FAU - Bai, Zichao
AU  - Bai Z
AD  - Department of Ophthalmology, The First hospital of Shanxi Medical University, 
      Taiyuan City.
FAU - Liu, Weiqin
AU  - Liu W
AD  - Wenzhou Medical University, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 1P05PW62F3 (KH902 fusion protein)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/administration & dosage/adverse effects/therapeutic use
MH  - Combined Modality Therapy/methods
MH  - Humans
MH  - Intravitreal Injections
MH  - Light Coagulation/*methods
MH  - Macular Edema/diagnostic imaging/*drug therapy/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Ranibizumab/administration & dosage/adverse effects/therapeutic use
MH  - Recombinant Fusion Proteins/administration & dosage/adverse effects/therapeutic 
      use
MH  - Retinal Vein Occlusion/*complications
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence
MH  - Visual Acuity/drug effects
PMC - PMC7249991
COIS- The authors report no funding and conflicts of interest.
EDAT- 2020/06/03 06:00
MHDA- 2020/06/19 06:00
PMCR- 2020/05/22
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/06/19 06:00 [medline]
PHST- 2020/05/22 00:00 [pmc-release]
AID - 00005792-202005220-00048 [pii]
AID - MD-D-19-03227 [pii]
AID - 10.1097/MD.0000000000020222 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 May 22;99(21):e20222. doi: 
      10.1097/MD.0000000000020222.